Filing Flows › BioMarin Pharmaceutical (BMRN) › Q3 2026
BioMarin Pharmaceutical (BMRN) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 3, 2026
BioMarin Pharmaceutical (BMRN) reported revenue of $1.0B for the third quarter 2026 (Q3 2026), +32% from a year earlier and +4% from the quarter before. Operating margin was -8.0%, net loss $123M (12.0% of revenue).
BioMarin Pharmaceutical, Q3 2026: revenue $1.0B (+32% year over year), operating margin -8.0%, net loss $123M, operating cash flow $188M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.0B | +4% | +32% |
| Operating profit | −$82.1M | -174% | — |
| Net earnings | −$123M | -374% | — |
| Operating cash flow | $188M | +12% | -49% |
| Free cash flow | $160M | +15% | -53% |
What changed
Revenue was $1.0B in Q3 2026, up 32% year over year and up 4% from the previous quarter. VOXZOGO was the largest line at 24% of revenue. VIMIZIM added $0.03B year over year (up 18%), 13% of the total change. Royalty and other revenues declined 25%.
Operating costs exceeded revenue by $0.08B, an operating margin of -8.0%. Total costs grew 35% against revenue growth of 32%. The fastest-growing cost line was Other operating costs (+7887%). The quarter ended with a net loss of $0.12B, after a profit of $0.04B the previous quarter.
Operating cash flow was $0.19B (down 49% year over year). Non-cash charges added back $0.13B of depreciation and amortization and $0.05B of share-based compensation. Working capital and other items added $0.13B. Capital expenditures of $0.03B left free cash flow of $0.16B.
Questions
What was BioMarin Pharmaceutical's revenue in the third quarter 2026?
BioMarin Pharmaceutical (BMRN) reported revenue of $1.0B for the third quarter 2026 (Q3 2026), +32% from a year earlier and +4% from the quarter before.
Was BioMarin Pharmaceutical profitable in the third quarter 2026?
Operating loss was $82.1M (-8.0% of revenue) and net loss $123M.